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ABSTRACT 
Background. Sepsis and subsequent multiple organ failure are the predominant causes of late 
mortality in trauma patients. Susceptibility and response to infection is, in part, heritable. 
Single nucleotide polymorphisms (SNPs) in Toll-Like Receptor (TLR) and Cluster of 
Differentiation 14 (CD14) genes of innate immunity may play a key role. The aim of this 
study was to assess if SNPs in TLR/CD14 predisposed trauma patients to infection. 
Methods. A prospective cohort of trauma patients (age 18-70 years, injury severity score ≥16) 
admitted to a Level I Trauma Center between January 2008 and April 2011 was genotyped for 
SNPs in TLR2 (T-16934A and R753Q), TLR4 (D299G and T399I), TLR9 (T-1486C and T-
1237C), and CD14 (C-159T) using High Resolution Melting Analysis (HRMA). Association 
of genotype with prevalence of positive cultures (Gram-positive, Gram-negative, fungi), 
systemic inflammatory response syndrome (SIRS), sepsis, septic shock, and mortality was 
tested with chi-square and logistic regression analysis. 
Results. Genotyping was performed for 219 patients, of which 51% developed a positive 
culture in sputum, wounds, blood, or urine. SIRS developed in 64%, sepsis in 36%, and septic 
shock in 17%. The TLR2 T-16934A TA genotype increased the risk of a Gram-positive 
infection (Odds Ratio, OR, 2.816; 95% CI 1.249-6.348; p=0.013) and SIRS (OR 2.386; 95% 
CI 1.011-5.632; p=0.047). Trends were noted for TLR9 and CD14 SNPS, but did not reach 
statistical significance. Sepsis and septic shock were unrelated to any of the SNPs studied. 
Conclusion. Aberrant functioning of the TLR/CD14 pathway of innate immunity changes the 
risk of infectious complications in severely injured trauma patients. Of the seven SNPs 
studied, the TLR2 T-16934A increased the risk, the TLR9 T-1486C SNPs may decrease the 
risk, TLR4 variation seemed unrelated to outcome. Early genotyping may prove to be helpful 
in the future in identifying polytraumatized patients at risk for infectious outcome. Level of 
Evidence II. Prognostic and epidemiological study. 
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INTRODUCTION 
 
Trauma is a leading cause of morbidity and mortality, and many polytraumatized patients 
require treatment in an Intensive Care Unit (1). Infectious complications are common after 
trauma and may substantially affect morbidity and mortality. Sepsis and subsequent multiple 
organ failure are the predominant causes of late mortality in polytraumatized patients; sepsis 
may occur in 3.1-17.0% and multiple-organ failure may occur in 1.6-9.0% of trauma patients 
(2). Immunogenetic biomarkers have been proposed as contributing factors in the 
development of trauma-induced infection and organ failure (3-5). 
Toll-like receptor (TLR) signalling plays an important role in the innate immune 
response and has been associated with the activation of inflammatory immune responses 
during trauma-induced infections (6, 7). TLRs recognize and bind to a wide range of 
pathogen-associated molecular patterns (PAMPs) on bacteria, viruses, fungi, and protozoa. 
This binding leads to the transcriptional activation of genes encoding for pro-inflammatory 
cytokines, chemokines, and co-stimulatory molecules, which subsequently control the 
activation of antigen-specific adaptive immune response (5, 8, 9). 
To date, ten different TLRs are described in humans (TLR1-10), each binding to 
different PAMPs and initiating specific immunological responses (10, 11). TLR2 
heterodimers bind polypeptides in the cell walls of bacteria and signal via MyD88 following 
initial interaction with Cluster of Differentiation 14 (CD14) (12, 13). TLR4 forms a 
homodimer complex with the MD-2 protein after initial binding of lipopolysaccharide (LPS) 
expressed by Gram-negative bacteria to CD14 (14). TLR9 is present in various cells of the 
immune system, such as dendritic cells and B- and T-cells and is situated intracellularly, 
bound to the endosome. TLR9 binds to the unmethylated cytosine guanine dinucleotide 
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(CpG) motifs, present in bacterial and viral DNA but also in our mitochondrial DNA. Thus 
this receptor recognizes pathogens as well as damaged tissue (9, 15). 
CD14 is a central pattern recognition molecule in innate immunity (16). It is found in 
association with TLRs on the surface of monocytes, macrophages, neutrophils, and 
hepatocytes (17, 18), and as a soluble form in serum (19). CD14 acts as coreceptor of TLR2 
and TLR4 for the detection of various microbial PAMPs (20), and initiates immune responses 
through TLR2 and TLR4 signalling (17, 21). 
There is growing evidence that susceptibility and response to infectious disease is, in 
part, heritable; particularly Single Nucleotide Polymorphisms (SNPs) in innate immune 
response genes may play a key role (22-25). Two important SNPS in the TLR2 gene (i.e., T-
16934A and R753Q) have been associated with Gram-positive infections, sepsis and septic 
shock (12, 13, 26). SNPs in the TLR4 gene (i.e., D299G and T399I) may alter the 
responsiveness of TLR4 to LPS, and increase the risk of Gram-negative sepsis, bacteremia, 
and mortality in patients admitted to the Intensive Care Unit (ICU) (4, 27, 28). SNPs in the 
TLR9 gene promoter (i.e., T-1237C and T-1486C), affect transcription regulation resulting in 
a disabled TLR9 function. A variant T-1273C genotype has been associated with increased 
susceptibility to viral pneumonia (29). The CD14 C-159T SNP has been associated with 
sepsis and Gram-negative bacteremia (26, 30, 31). 
The aim of this study was to assess the relevance of SNPs in TLR2, TLR4, TLR9, and 
CD14 for infectious complications in trauma patients. We hypothesized that these SNPs are 
associated with increased prevalence of positive cultures (Gram-positive and Gram-negative 
bacteria and fungi), systemic inflammatory response syndrome (SIRS), sepsis, and septic 
shock in trauma patients. 
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MATERIALS AND METHODS 
 
Patients and Data Collection 
A prospective cohort of consecutive polytraumatized patients admitted to a Level I Trauma 
Center (Rotterdam, The Netherlands) between January 2008 and April 2011 was studied. 
Eligibility criteria were an Injury Severity Score (ISS) (32) of 16 or higher and age 18-80 
years. Patients with a known immune disorder or those taking immunosuppressive medication 
were excluded. Patients with a neutrophil count of <1x109 cells/L before the onset of sepsis, 
infections associated with burns, or lack of commitment to full life-support measures by the 
primary physician were also excluded. The ISS score was calculated using the ISS update 98. 
After obtaining written informed consent from patient or proxy a blood sample was taken in 
an EDTA tube and stored at -80°C until use. The study was approved by the local medical 
research ethics committee and the trial was registered in the Dutch Trial Registry (NTR1625) 
before patient recruitment. 
Cultures were taken on a standardized routine basis or at the discretion of the 
physician based upon clinical signs. Endpoints used were: positive cultures during hospital 
stay, mortality, SIRS within the first 24 hours of admission and developing sepsis or septic 
shock during hospital admission. SIRS, sepsis, and septic shock were defined using 
international criteria (33). The following data were retrieved from electronic files: age at 
trauma, trauma mechanism, ISS score, length of stay in the Intensive Care Unit and the 
hospital, all positive cultures from blood, urine, sputum, wounds, or other positive cultures 
during hospital stay, if patients developed SIRS within 24 hours of hospital admission and 
sepsis or septic shock during the hospital stay, and if applicable the cause of death. 
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 DNA Isolation 
Genomic DNA was isolated from 300 µL EDTA-treated peripheral blood using the QIAamp® 
DNA Blood Mini kit (QiaGen Benelux, Venlo, The Netherlands), according to the 
manufacturer’s instructions. The purity (A260nm/A280nm index) and concentration of the 
isolated DNA samples were determined with the Thermo Scientific Nanodrop TM1000 
spectrophotometer (Isogen Life Science, De Meern, The Netherlands). Samples were diluted 
to 10 ng/µL using Milli-Q and were stored at 4°C until use. 
 
PCR Oligonucleotides 
Details on the SNPs studied are given in Table 1. SNP data were retrieved from Ensembl.org, 
National Center for Biotechnology Information (NCBI) GenBank, and NCBI SNP Database. 
All oligonucleotides (see Table 2) were purchased from Eurogentec (Seraing, Belgium). For 
the High Resolution Melting Analysis (HRMA) 18-20 nucleotides upstream and downstream 
of the SNPs were used as forward and reverse primers. Oligonucleotides for direct sequencing 
were designed using the Oligo 6.22 software (Molecular Biology Insight, Cascade, CO, USA) 
and resulted in 400-555 base pair amplicons. Oligonucleotides had melting temperatures (Tm) 
between 65.0-66.5°C (Tm calculated using the nearest neighbour method at a salt 
concentration of 50mM KCl and 4mM MgCl2 (303mM of Na+ equivalent) and 300nM 
oligonucleotides). 
 
Genotyping 
 SNPs were detected using HRMA (34). Polymerase chain reactions (PCRs) were performed 
in a total volume of 10 µL, containing 20ng genomic DNA, 5pmol of both gene-specific 
oligonucleotides, 2pmol dNTPs (Promega, Madison, WI, USA), 1µL LC-green (Bioké, 
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Leiden, The Netherlands), 0.5U of Taq DNA polymerase (Roche Diagnostics, Almere, The 
Netherlands), and 1µl 10x PCR buffer containing 20mM MgCl2. Two pmoles of calibrator 
oligonucleotides were added for calibration of melting curves. The PCR was run on a 
Biometra Thermocycler (Biometra GmbH, Göttingen, Germany). The thermocycling program 
included denaturation at 95°C for 10 min, followed by 55 cycles of 20 sec at 95°C, 30 sec at 
60°C and 40 sec at 72°C, and a final extension step of 5 min at 72°C. HRMA was performed 
using a LightScanner® (HR-96, Idaho Technology, Salt Lake City, UT, USA). Melting was 
done from 55°C to 98°C at 0.1°C/sec. Melting curves were analyzed with the LightScanner® 
Software using Call-IT 1.5. 
All variant genotypes found were confirmed by direct sequencing. PCR were 
performed in a total volume of 25 µL, containing 50 ng genomic DNA, 4mM MgCl2, 3pmol 
of both oligonucleotides, 2pmol dNTPs, 1.0U Taq DNA polymerase, and 1µl 10x PCR buffer 
without MgCl2. The thermocycling program included denaturation at 95°C for 5 min, 
followed by 35 cycles of 30 sec at 95°C, 1 min at 60°C, and 1 min at 72°C, and a final step of 
7 min at 72°C. Amplicon purification and sequencing was performed by BaseClear (Leiden, 
The Netherlands). Results were analyzed using the SeqMan® analysis software. 
 
Data Analysis 
Allele frequencies for each SNP were determined by gene counting. The genotype 
distribution of each SNP was tested for departure from the Hardy-Weinberg equilibrium by 
means of χ2 analysis. Data were analyzed using the Statistical Package for the Social 
Sciences, version 16.0 (SPSS, Chicago, IL, USA). Categorical variables were analyzed using 
a χ2 test or a Fischer’s exact test in order to determine whether the SNPs predisposed for a 
higher risk of any of the endpoints. A Mann-Whitney U-test was used for statistical analysis 
of numeric variables. Binary logistic regression models were developed in order to model the 
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relation between different covariates and the occurrence of an infectious complication. 
Herein, age, gender, injury severity score, and trauma mechanism (i.e., blunt or penetrating 
injury) were added as covariates. A p-value of <0.05 was considered to be significant.  
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RESULTS 
 
Patient demographics and genotype frequencies 
From January 2008 to April 2011, 219 patients were included. Of all patients 177 (77.6%) 
were male, the median age was 44 years (P25-P75 27-56) and the median ISS score was 25 
(P25-P75 18-29). A total of 13 patients (5.9%) sustained penetrating trauma and 159 patients 
(72.6%) were admitted to the ICU with a median stay of 3 days (P25-P75 0-14). Trauma 
mechanisms included traffic accidents (48.9%), fall from height (32.4%), crush injury to the 
chest (4.1%), head injuries with axes or screwdrivers (2.7%), gunshot injuries (2.3%), 
horseback injuries, street fighting, stab wounds (1.8%), and miscellaneous injuries like ice 
skating, helicopter crash, fireworks or collapsing buildings. 
 
HRMA results showed that TLR2 T-16934A rare alleles were abundantly present; 58 (26.5%) 
patients had a homozygous AA genotype, 111 (50.7%) had a heterozygous TA genotype, and 
50 (22.8%) carried a wild-type TT genotype. For the TLR2 R753Q SNP, 15 (6.8%) patients 
carried the heterozygote RQ and 204 (93.2%) a RR genotype. For the TLR4 D299G SNP 190 
(86.8%) had a DD, and 28 (12.8%) a DG genotype. The TLR4 T399I SNP cosegregated with 
D299G in 217 (99.1%) patients; 191 (87.2%) had a TT, 26 (11.9%) a TI, and 2 (0.9%) an II 
genotype. For the TLR9 T-1486C SNP, 80 (36.5%) had a TT, 100 (45.7%) a TC, and 39 
(17.8%) a CC genotype. For the TLR9 T-1237C SNP, 160 (73.1%) had a TT, 52 (23.7%) a 
TC, and 7 (3.2%) a CC genotype. For the CD14 C-159T SNP, 59 (26.9%) had a CC, 105 
(47.9%) a CT, and 55 (25.2%) a TT genotype. The genotype distribution of all SNPs was in 
agreement with the Hardy-Weinberg equilibrium (χ2=0.01-1.149; P=0.275-0.997). 
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Effect of genotype on infectious complications 
Table 3 shows an overview of infectious complications encountered separated by genotype. 
Overall, Gram-positive bacteria were detected in 79 patients, Gram-negative bacteria in 84 
and fungi in 46 patients. Approximately half of the patients (51.1%) developed a positive 
culture; this was mostly in sputum (N=70), but positive cultures were also found in wounds 
(N=36), blood (N=32), and urine (N=32). Overall, 139 patients developed SIRS within 24 
hours, of which 79 developed sepsis and 37 septic shock. Thirteen (5.9%) patients died. 
 
Table 4 shows the results of the multivariable logistic regression models. Sustaining a Gram-
positive infection was statistically significantly increased in patients with a TLR2 T-16934A 
TA genotype (Odds Ratio, OR, 2.816; 95%CI 1.249-6.348; p=0.013). Forty-one percent of 
TA patients cultured a Gram-positive bacterium versus 24.0% of wildtype patients (Table 3). 
A TLR9 T-1486C rare allele, on the other hand, seemed to result in decreased Gram-positive 
rates (31.0% in TC and 30.8% in CC versus 45.0% in wildtypes), however this did not reach 
statistical significance in the multivariable analyses (p=0.066 for TC and p=0.079 for CC). 
 None of the SNPs affected the risk of Gram-negative cultures or fungi. Although the 
rate of positive fungal cultures seemed reduced in patients with a TLR9 T-1486C TC genotype 
(14.0% versus 27.5% in wildtypes) and increased in patients with a CD14 C-159T CT 
genotype (23.8% versus 13.6% in wildtypes), both were not statistically associated with 
outcome in multivariable analyses (p=0.060 and 0.072, respectively). 
 As for the location of the positive cultures, the TLR2 T-16934A AA genotype was 
significantly associated with fewer positive urine cultures (OR 0.230; 95%CI 0.060-0.886; 
p=0.033). Blood cultures occurred in 17.1% of TLR2 T-16934A TA patients (versus 8.0% in 
TT) and in 23.1% of TLR9 T-1237C TC patients (versus 12.5% in TT), but both were not 
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statistically significant in multivariable analysis (p=0.065 and p=0.076, respectively). The 
occurrence of sputum and wound cultures was unrelated to any of the SNPs studied. 
The occurrence of SIRS in the first 24 hours of hospital admission was statistically 
significantly increased in patients with a TLR2 T-16934A TA genotype (OR 2.386; 95%CI 
1.011-5.632; p=0.047), but unrelated to any of the other SNPs. Sepsis and septic shock were 
unrelated to TLR2, TLR4, TLR9, and CD14 SNPs. 
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DISCUSSION 
 
In this study we showed that severely injured trauma patients with an inadequately 
functioning TLR pathway due to SNPs in TLR2 and, to a lesser extent, in TLR9 are at 
increased risk of infectious complications. 
The genotype distributions of all polymorphisms studied in our trauma patient cohort 
were in agreement with published data (4, 13, 26, 28-30, 35-41). The genotype distributions 
of all SNPs were in agreement with the Hardy-Weinberg equilibrium model. 
Patients with a TLR2 T-16934A TA genotype were more prone to Gram-positive 
infections, and presence of homozygous AA alleles predisposed patients to SIRS. Sutherland 
et al. showed that this SNP is a risk factor for sepsis and Gram-positive bacteremia in 
critically ill patients in the ICU (26). We were unable to confirm their findings related to 
sepsis; 38.7% of our trauma patients with a TA genotype developed sepsis versus 36.0% of 
patients with a TT genotype. We found a 2-fold higher rate of positive blood culture in the TA 
group compared with the TT group (p=0.065). More patients are needed to reach statistical 
significance. Our finding that the T-16934A AA genotype was associated with fewer positive 
urine cultures (N=4) has not been shown before. Only Gram-negative bacteria were found. 
The TLR2 R753Q SNP has been associated with increased prevalence of Gram-
positive infections, staphylococcal infections, sepsis, and septic shock (12, 13, 28, 42), but 
others reported that this SNP did not affect the risk of bacteremia in Caucasian patients 
admitted to the ICU (4). With only 6.8% having an RQ genotype and complete absence of a 
QQ genotype, our study was inadequately powered to find any associations with outcome in 
trauma patients. If this SNP were relevant, it would only be so in a small subset of patients. 
TLR4 is important in the defense against bacteria, particularly Gram-negative bacteria. 
Since both the D299G and T399I SNP are associated with decreased TLR4 function it is 
 12 
remarkable that we did not find any association of these SNPs with infection susceptibility. 
However, both SNPs were previously shown to be unrelated to outcome of Gram-negative 
sepsis (43) and to sepsis in trauma patients with SIRS in the ICU (13). Several other studies, 
however, did in fact imply that TLR4 polymorphisms were related to increased susceptibility 
to infections and sepsis in burn patients (44) or in patients admitted to an ICU (4, 28, 42, 45). 
Shalhub et al. showed that a TLR4 D299G variant G allele caused a decreased rate of 
complicated sepsis in Caucasian trauma patients admitted to the ICU (45). Our multivariable 
analysis did not support an association between genotype and infection or outcome of sepsis; 
almost 50% of patients with sepsis developed septic shock, both in the DG and TI group (5 of 
11 patients) and in wildtypes (32 of 68 patients).  
Our data support the findings of Henckaerts et al. Who showed that a TLR4 D299G 
variant genotype resulted in a 2-fold increase of bacteremia in ICU patients (4). 
Reduced expression of TLR9 could render patients more susceptible to pathogens, yet 
increased TLR9 expression after stimulation by damage-associated molecular patterns 
(DAMPs) could trigger an exaggerated immune response (15, 46, 47). The TLR9 T-1486C 
SNP has been associated with sepsis and multiple organ dysfunction (MOD) in trauma 
patients (37), puerperal group A streptococcal sepsis (48), and invasive fungal infections in 
paediatric patients receiving chemotherapy (49). We found a trend towards reduced 
prevalence of Gram-positive bacteria and fungi for this SNP (p=0.060-0.066), but no 
significant association with SIRS, sepsis, or septic shock. As opposed to our results, however, 
Chen et al. showed that patients with a T-1486C variant genotype were at increased risk of 
sepsis (OR 1.36) and had slightly increased MOD scores (37). 
We found a trend towards increased risk of positive blood cultures the T-1237C TC 
genotype (p=0.076), but no significant association with SIRS, sepsis, or septic shock. In 
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agreement with our data, Chen et al. found no association between TLR9 T-1237C variant 
genotype and infection in severe blunt trauma patients (37).  
 The CD14 C-159T SNP reduces the promoter activity of CD14, resulting in decreased 
TLR2/4 downstream signalling. A CT or TT genotype has been associated with increased 
rates of positive bacterial culture findings and Gram-negative sepsis in critically ill patients 
(26, 30, 31, 41). However, in other studies this SNP was not associated with altered risk of 
Gram-negative infection or sepsis in critically ill patients (28, 51), and was unrelated to sepsis 
prevalence and severity in trauma patients (45, 52). Our data support the latter. 
 A limitation of our study is that we retrospectively collected data on clinical 
manifestations of infection like SIRS, sepsis, and septic shock. Also, cultures were initially 
collected at the discretion of the physician based on clinical parameters but during the study 
protocols changed towards routine culturing of all patients. 
 The human innate immune system consists of more pathways in addition to the 
TLR/CD14 pathway. The advantage of our study is that the growing DNA bank of severely 
injured trauma patients enables us to increase the panel of SNP assays or even perform a 
genome-wide SNP analysis. 
 
In summary, our data showed that an aberrant functioning of the TLR/CD14 pathway due to 
presence of the TLR2 T-16934A polymorphism predisposed severely injured trauma patients 
to increased risk of developing an infectious complication. The TLR9 T-1486C SNPs on the 
other hand may reduce the risk of positive culture findings, and TLR4 variation was unrelated 
to infection. Additional research is needed in order to fully understand the roles these SNPs 
play in the complex injury and infection processes. 
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Table 1. Positions of SNPs and their corresponding nucleotide and amino acid transition 
Gene SNP dbSNP ID Nucleotide 
transition 
(Accesion code) 
Amino-Acid 
transition 
(Accesion code) 
Location on gene / Domain 
TLR2 T-16934A rs4696480 6686T>A N.A. Promoter, 5’ untranslated region 
 R753Q rs5743708 
 
25877G>A 
(NG_016229.1) 
Arg753Gln 
(NP_003255.2) 
Exon 3; Toll/Interleukin-1 
receptor (TIR) domain 
      
TLR4 D299G rs4986790 13843A>G Asp299Gly Exon 3 Extracellular domain 
 T399I rs4986791 14143C>T 
(NG_011475.1) 
Thr399Ile 
(NP_612564.1) 
Exon 3 Extracellular domain 
      
TLR9 T-1486C rs187084 52261031A>G N.A. Promoter, 5’ untranslated region 
 T-1237C rs5743836 52260782A>G 
(NC_000003.11) 
N.A. Promoter, 5’ untranslated region 
      
CD14 C-260T rs2569190 5371T>C 
(NG_023178.1) 
N.A. Promoter, 5’ untranslated region 
SNP, Single Nucleotide Polymorphism; 
Amino acids: Arg (R), Arginine; Asp (D), Asparctic acid; Gln (Q), Glutamine; Gly (G), 
Glycine; Ile (I), Isoleucine; Thr (T), Threonine.
 21 
Table 2. Oligonucleotide sequence for primers and probes used in TLR2, TLR4, TLR9, and CD14 genotyping 
Name 
(Accession code) 
SNP Assay Primer Start 
Position 
Sequence Amplicon size 
(base pairs) 
Calibrators - HRMA Forward - 5’-TTAAATTATAAAATATTTATAATATTAATTATATA 
 TATATAAATATAATA-Amine-C6-3’ 
50 
   Reverse - 5’-TATTATATTTATATATATATAATTAATATTATAAA 
 TATTTTATAATTTAA-Amine-C6-3’ 
 
TLR2 T-16934A HRMA Forward 6666 5’-GATTGAAGGGCTGCATCTGG-3’ 41 
(NG_016229.1)   Reverse 6687 5’-AATGTAGCCAGATGACCCTC-3’  
  Sequencing Forward 6401 5’-TTGGGGGTTTCTAAGCTAT-3’ 406 
   Reverse 6790 5’-TCACCAAGGGAGCAGTT-3’  
 R753Q  HRMA Forward 25857 5’-CCAGCGCTTCTGCAAGCTGC-3’ 41 
   Reverse 25878 5’-TCTTGGTGTTCATTATCTTC -3’  
  Sequencing Forward 25622 5’-CCCCCTTCAAGTTGTGT-3’ 468 
   Reverse 26071 5’-CCTCAAATGACGGTACATC-3’  
TLR4 D299G HRMA Forward 13817 5’-AGCATACTTAGACTACTACCT-3’ 53 
(NG_011475.1)   Reverse 13849 5’-TCAAACAATTAAATAAGTCAA-3’  
  Sequencing Forward 13576 5’-TGTCCCTGAACCCTATGA-3’ 501 
   Reverse 14057 5’-ACTCAAGGCTTGGTAGATCA-3’  
 T399I HRMA Forward 14223 5’-TCAAAGTGATTTTGGGACAA-3’ 41 
   Reverse 14241 5’-GATCTAAATACTTTAGGCTG-3’  
  Sequencing Forward 14035 5’-GTGGGAATGCTTTTTCAG-3’ 552 
   Reverse 14567 5’-GGAGGGAGTTCAGACACTTA-3’  
TLR9 T-1486C HRMA Forward 52261011 5’-AGATAAAAGATCACTGCCCT-3’ 41 
(NC_000003.11)   Reverse 52261032 5’-TGCTGGAATGTCAGCTTCTT-3’  
 T-1237C HRMA Forward 52260762 5’-TATGAGACTTGGGGGAGTTT-3’ 41 
   Reverse 52260783 5’-TGTGCTGTTCCCTCTGCCTG-3’  
 Both SNPs Sequencing Forward 52260931 5’-CTGACTGCTGGGTGTACAT-3’ 508 
   Reverse 52260925 5’-AAAGCCACAGTCCACAGA-3’  
CD14 C-260T HRMA Forward 5352 5’-AGAATCCTTCCTGTTACGG-3’ 41 
(NG_023178.1)   Reverse 5373 5’-AAGGATGTTTCAGGGAGGGG-3’  
  Sequencing Forward 5180 5’-ATTGGGGGGTTGGATAG-3’ 443 
   Reverse 5604 5’-AGTCTTCCGAACCTCTGAG-3’  
HRMA, High-Resolution Melting Analysis. 
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Table 3: Demographic description of positive cultures and infectious complications by genotype 
  N Gram- 
Positive 
Gram- 
Negative 
Fungus Sputum 
Culture 
Blood 
Culture 
Urine 
Culture 
Wound 
Culture 
SIRS * Sepsis * Septic 
Shock * 
Mortality 
Entire population  219 79 (36.1) 84 (38.4) 46 (21.0) 70 (32.0) 32 (14.6) 32 (14.6) 36 (16.4) 139 (63.5) 79 (36.1) 37 (16.9) 13 (5.9) 
              
TLR2 T-16934A TT 50 12 (24.0) 21 (42.0) 8 (16.0) 15 (30.0) 4 (8.0) 9 (18.0) 8 (16.0) 28 (56.0) 18 (36.0) 9 (18.0) 2 (4.0) 
 TA 111 46 (41.4) 42 (37.8) 28 (25.2) 36 (32.4) 19 (17.1) 19 (17.1) 17 (15.3) 70 (63.1) 43 (38.7) 18 (16.2) 8 (7.2) 
 AA 58 21 (36.2) 21 (36.2) 10 (17.2) 19 (32.8) 9 (15.5) 4 (6.9) 11 (19.0) 41 (70.7) 18 (31.0) 10 (17.2) 3 (5.2) 
              
TLR2 R753Q RR 204 73 (35.8) 80 (39.2) 46 (22.5) 66 (32.4) 31 (15.2) 31 (15.2) 35 (17.2) 130 (63.7) 74 (36.3) 36 (17.6) 13 (6.4) 
 RQ 15 6 (40.0) 4 (26.7) 0 (0.0) 4 (26.7) 1 (6.7) 1 (6.7) 1 (6.7) 9 (60.0) 5 (33.3) 1 (6.7) 0 (0.0) 
 QQ 0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
              
TLR4 D299G DD 190 70 (36.8) 73 (38.4) 40 (21.1) 61 (32.1) 27 (14.2) 30 (15.8) 34 (17.9) 118 62.1) 68 (35.8) 32 (16.8) 10 (5.3) 
 DG 28 9 (32.1) 11 (39.3) 6 (21.4) 9 (32.1) 5 (17.9) 2 (7.1) 2 (7.1) 20 (71.4) 11 (39.3) 5 (17.9) 3 (10.7) 
 GG 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100) 0 (0.0) 0 (0.0) 0 (0.0) 
              
TLR4 T399I TT 191 70 (36.6) 74 (38.7) 41 (21.5) 62 (32.5) 27 (14.1) 30 (15.7) 35 (18.3) 119 (62.3) 69 (36.1) 33 (17.3) 10 (5.2) 
 TI 26 8 (30.8) 9 (34.6) 5 (19.2) 8 (30.8) 5 (19.2) 1 (3.8) 1 (3.8) 19 (73.1) 10 (38.5) 4 (15.4) 3 (11.5) 
 II 2 1 (50.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0) 0 (0.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 
              
TLR9 T-1486C TT 80 36 (45.0) 34 (42.5) 22 (27.5) 27 (33.8) 15 (18.8) 12 (15.0) 19 (23.8) 51 (63.8) 31 (38.8) 17 (21.2) 4 (5.0) 
 TC 100 31 (31.0) 34 (34.0) 14 (14.0) 32 (32.0) 10 (10.0) 10 (10.0) 12 (12.0) 62 (62.0) 33 (33.0) 14 (14.0) 7 (7.0) 
 CC 39 12 (30.8) 16 (41.0) 10 (25.6) 11 (28.2) 7 (17.9) 10 (25.6) 5 (12.8) 26 (66.7) 15 (38.5) 6 (15.4) 2 (5.1) 
              
TLR9 T-1237C TT 160 57 (35.6) 60 (37.5) 34 (21.2) 49 (30.6) 20 (12.5) 26 (16.3) 26 (16.3) 100 (62.5) 55 (34.4) 23 (14.4) 6 (3.8) 
 TC 52 20 (38.5) 21 (40.4) 9 (17.3) 19 (36.5) 12 (23.1) 5 (9.6) 7 (13.5) 34 (65.4) 21 (40.4) 12 (23.1) 7 (13.5) 
 CC 7 2 (28.6) 3 (42.9) 3 (42.9) 2 (28.6) 0 (0.0) 1 (14.3) 3 (42.9) 5 (71.4) 3 (42.9) 2 (28.6) 0 (0.0) 
              
CD14 C-159T CC 59 20 (33.9) 22 (37.3) 8 (13.6) 20 (33.9) 11 (18.6) 8 (13.6) 7 (11.9) 38 (64.4) 22 (37.3) 10 (16.9) 3 (5.1) 
 CT 105 36 (34.3) 37 (35.2) 25 (23.8) 36 (34.3) 14 (13.3) 13 (12.4) 14 (13.3) 69 (65.7) 37 (35.2) 15 (14.3) 8 (7.6) 
 TT 55 23 (41.8) 25 (45.5) 13 (23.6) 14 (25.5) 7 (12.7) 11 (20.0) 15 (27.3) 32 (58.2) 20 (36.4) 12 (21.8) 2 (3.6) 
* SIRS, sepsis, and septic shock were only determined for patients admitted to the Intensive Care Unit. 
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Table 4: Association between genotype and infections outcome in polytraumatized patients 
 
  Gram- 
Positive 
Gram- 
Negative 
Fungus Sputum 
Culture 
Blood 
Culture 
Urine 
Culture 
Wound 
Culture 
SIRS Sepsis Septic 
Shock 
  Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio 
TLR2 T-16934A TA 2.816 * 
(1.249-6.348) 
0.908 
(0.436-1.892) 
1.793 
(0.684-4.700) 
1.246 
(0.580-2.677) 
3.194 
(0.929-10.982) 
0.864 
(0.323-2.316) 
0.763 
(0.281-2.077) 
1.514 
(0.730-3.143) 
1.230 
(0.614-2.879) 
0.913 
(0.353-2.359) 
 AA 2.114 
(0.851-5.248) 
 
0.817 
(0.352-1.895) 
1.243 
(0.406-3.746) 
1.290 
(0.540-3.082) 
2.748 
(0.701-10.780) 
0.230 * 
(0.060-0.886) 
1.303 
(0.438-3.873) 
2.386 * 
(1.011-5.632) 
0.996 
(0.408-2.430) 
1.126 
(0.386-3.279) 
TLR2 R753Q RQ 0.859 
(0.266-2.782) 
 
0.356 
(0.099-1.288) 
N.D. 0.583 
(0.167-2.033) 
0.240 
(0.025-2.272) 
0.283 
(0.032-2.521) 
0.297 
(0.035-2.554) 
0.805 
(0.260-2.497) 
0.559 
(0.162-1.933) 
0.215 
(0.024-1.923) 
TLR4 D299G§ DG 0.640 
(0.248-1.654) 
0.898 
(0.369-2.189) 
0.946 
(0.304-2.947) 
0.846 
(0.337-2.123) 
1.170 
(0.328-4.173) 
0.390 
(0.078-1.958) 
0.322 
(0.068-1.525) 
1.277 
(0.505-3.233) 
0.946 
(0.375-2.283) 
0.957 
(0.299-3.059) 
 GG N.D. 
 
N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
TLR9 T-1486C TC 0.532 
(0.271-1.043) 
0.735 
(0.376-1.436) 
0.447 
(0.193-1.036) 
0.916 
(0.463-1.811) 
0.489 
(0.186-1.287) 
0.454 
(0.163-1.263) 
0.511 
(0.214-1.218) 
1.028 
(0.527-2.004) 
0.913 
(0.454-1.833) 
0.757 
(0.320-1.791) 
 CC 0.456 
(0.190-1.096) 
 
0.934 
(0.401-2.176) 
0.791 
(0.296-2.113) 
0.761 
(0.310-1.870) 
0.976 
(0.315-3.021) 
1.928 
(0.650-5.716) 
0.397 
(0.127-1.232) 
1.144 
(0.479-2.730) 
1.022 
(0.416-2.510) 
0.727 
(0.241-2.188) 
TLR9 T-1237C TC 0.994 
(0.479-2.066) 
1.170 
(0.569-2.405) 
0.534 
(0.201-1.422) 
1.108 
(0.534-2.299) 
2.365 
(0.915-6.111) 
0.501 
(0.159-1.274) 
0.743 
(0.273-2.019) 
1.185 
(0.571-2.447) 
1.413 
(0.672-2.971) 
1.905 
(0.782-4.643) 
 CC 0.522 
(0.085-3.218) 
 
1.107 
(0.215-5.707) 
2.751 
(0.434-17.426) 
1.004 
(0.168-5.996) 
N.D. 0.620 
(0.058-6.663) 
4.033 
(0.635-25.609) 
2.062 
(0.334-12.717) 
1.491 
(0.270-7.239) 
2.263 
(0.353-14.490) 
CD14 C-159T CT 0.858 
(0.411-1.788) 
0.864 
(0.420-1.779) 
2.473 
(0.923-6.630) 
0.987 
(0.479-2.034) 
0.538 
(0.199-1.457) 
0.713 
(0.249-2.037) 
1.377 
(0.475-3.992) 
1.122 
(0.543-2.322) 
0.842 
(0.399-1.774) 
0.843 
(0.323-2.202) 
 TT 1.309 
(0.573-2.991) 
 
1.408 
(0.627-3.164) 
2.265 
(0.765-6.706) 
0.667 
(0.281-1.584) 
0.545 
(0.171-1.742) 
1.746 
(0.563-5.415) 
2.563 
(0.869-7.557) 
0.709 
(0.312-1.613) 
0.829 
(0.354-2.942) 
1.379 
(0.495-3.842) 
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Multivariable logistic regression models were made for all individual outcome measure (i.e., positive culture or infectious complication) as 
dependent variable. Age, gender, trauma mechanism, ISS, and individual SNPs were entered as covariate. Data are shown as odds ratio, with the 
95% CI between brackets. For all SNPs the wildtype genotype was used as reference category. Male gender and blunt trauma were used as 
reference categories for gender and trauma mechanism, respectively. 
§Since the TLR4 D299G and T399I SNPs cosegregated in >99% of patients, only the D299G SNP was used for designing a multivariable model. 
N.D., not determined due to insufficient numbers. 
Statistically significant data are indicated in boldface. * P < 0.05; ** P < 0.01; *** P < 0.005; **** P < 0.001. 
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